ArticleInternational journal of cardiology2025
Utilization rates and determinants of PYP and CMR among patients with unexplained left ventricular hypertrophy on echocardiography.
Article in International journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCardiac amyloidosis (CA) is an underdiagnosed cause of heart failure with a poor prognosis if left untreated. Echocardiography provides an excellent screening tool, but it is unknown how frequently patients with features consistent with CA undergo further testing.
methodsThe study aims to investigate the rates of cardiac MRI (CMR) and PYP scan utilization and identify the clinical and echocardiographic factors associated with their use. We performed a retrospective cohort study from December 2018 to September 2020. Patients age ≥ 18 years with echocardiographic features consistent with CA were included (moderate or greater concentric left ventricular hypertrophy plus moderate or severe diastolic dysfunction). We estimated multiple logistic regression models to identify factors associated with subsequent testing with CMR or PYP.
resultsOf 1015 patients, 83 patients (8.2 %) underwent further testing. On multivariable analysis, factors associated with further testing include age 65+ years (aOR: 2.27; 95 % CI: 1.31-3.96; p = 0.004), Black race (aOR: 1.76; 95 % CI: 1.04-2.99; p = 0.036), diagnosis of HFrEF (aOR: 2.08; 95 % CI: 1.04-4.17; p = 0.040), severe diastolic dysfunction (aOR: 2.14; 95 % CI: 1.24-3.67; p = 0.006), severe wall thickness (aOR: 2.66; 95 % CI: 1.52-4.66; p = 0.001), and echocardiogram ordered by a cardiologist (aOR: 1.95; 95 % CI: 1.19-3.20; p = 0.009).
conclusionAmong patients with echocardiographic features consistent with CA, follow-up testing remains low. Features consistent with advanced disease were associated with follow-up testing for CA, suggesting the need to implement strategies to better identify patients earlier in the disease process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.